IceCure Medical (ICCM) Cash from Financing Activities (2020 - 2026)

IceCure Medical (ICCM) has reported Cash from Financing Activities for 7 consecutive years, with $7.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 273.24% year-over-year to $7.8 million in Q2 2026; TTM through Jun 2026 was $22.5 million, a 147.13% increase from a year earlier, with the FY2025 full-year figure at $15.8 million, up 72.35% from the prior year.
• Cash from Financing Activities was $7.8 million for Q2 2026 at IceCure Medical, up from $3.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $13.6 million in Q4 2022 and troughed at $68000.0 in Q4 2023.
• A 5-year average of $4.2 million and a median of $3.1 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 99.5% in 2023 and soared 1519.12% in 2024, its largest moves.
• Over 5 years, Cash from Financing Activities stood at $13.6 million in 2022, then tumbled by 99.5% to $68000.0 in 2023, then soared by 1519.12% to $1.1 million in 2024, then surged by 237.87% to $3.7 million in 2025, then surged by 109.19% to $7.8 million in 2026.
• The last three Cash from Financing Activities figures came in at $7.8 million (Q2 2026), $3.5 million (Q1 2026), and $3.7 million (Q4 2025), per Business Quant data.